The safety of sildenafil among infertile women has not been established, although no increased incidence of adverse events has been observed based on limited information. Most of the reported ...

Daré Bioscience, in collaboration with Strategic Science & Technologies, announced plans for a Phase 3 clinical study of Sildenafil Cream, 3.6%, aimed at treating female sexual arousal disorder ...

This story was reviewed by Mike Bohl, MD. In the ‘80s, researchers set out to test a medication called sildenafil citrate for treating high blood pressure and angina (chest pain) from heart disease.

We are excited about the potential for Daré’s Sildenafil Cream formulation to address this critical unmet need in women's sexual health, and that there is a clear path forward on how to ...

To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA approval for FSAD. Market research estimates approximately 10 ...

Purpose: The stability of sildenafil citrate 2.5 mg/mL in two extemporaneously prepared oral suspensions stored at 4 and 25 ºC was studied. Methods: Thirty 25-mg tablets of sildenafil citrate ...

FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved pharmacological treatments for FSAD; Daré's Sil ...

Methods: This randomised, double blind (DB), placebo controlled, flexible dose study with an open label extension (OLE) assessed efficacy, QoL, and safety of sildenafil citrate in men with MS and ED.